Kimchi-Derived Probiotics Slashed Uric Acid by 32% in Mice. Could Gout Sufferers Be Next?

Traditional fermented foods have fed human gut bacteria for millennia, but a new study suggests one of them may carry a specific biochemical payload against hyperuricemia, a condition where uric acid builds up in the blood to levels that damage kidneys, trigger gout, and raise cardiovascular risk. Researchers at Northeast Forestry University isolated two bacterial strains from Northeast Chinese kimchi (paocai), combined them into a probiotic consortium, and found the combination cut serum uric acid by 32.57% in hyperuricemic mice. The work is early and animal-only, but the mechanistic detail is striking enough to warrant attention.

How Elevated Uric Acid Quietly Damages Organs

Hyperuricemia affects an estimated 38 million Americans and is rising globally, with rates reaching 20.2% in men and 20.0% in women in the United States between 2015 and 2016. In China, prevalence climbed from 13.3% in 2014 to 17.7% in 2017. The condition is more than a gout precursor: elevated uric acid is linked to chronic kidney disease, fatty liver, metabolic syndrome, and cardiovascular complications. Current drug treatments, including allopurinol and febuxostat, work, but they carry risks ranging from dermal adverse reactions to cardiovascular concerns and organ intolerance, which has pushed researchers toward dietary and probiotic alternatives.

The gut plays a surprisingly direct role in this. Research on how gut microbiota regulate serum uric acid shows that certain microbes can produce uricolytic enzymes, strengthen the intestinal barrier, and inhibit uric acid production and reabsorption in the liver and kidneys. That biochemical leverage is exactly what the kimchi strains appear to exploit.

Lacticaseibacillus paracasei NEFU-3 and NEFU-4: What the Strains Actually Do

Aman Khan and colleagues identified two strains, Lacticaseibacillus paracasei NEFU-3 and NEFU-4, from traditional Northeast Chinese kimchi. Tested separately, NEFU-3 degraded 30.22% of uric acid in vitro, NEFU-4 degraded 24.26%. Mixed in a 1:1 ratio to form a probiotic consortium, they degraded 41.93%, a synergistic jump that outperformed either strain alone. HPLC analysis confirmed that the degradation product was urea, meaning the bacteria were actually metabolizing uric acid through a defined biochemical route rather than merely sequestering it.

Functional genomic analysis using PICRUSt2 pinpointed the enzymatic machinery: the consortium showed enrichment in urate oxidase (EC 1.7.3.3), glyoxylate reductase (EC 1.1.1.26), 5-hydroxyisourate hydrolase (EC 3.5.2.17), and allantoinase (EC 3.5.2.5). These enzymes form a stepwise uric acid degradation pathway. The consortium also outperformed individual strains on DPPH and ABTS free-radical scavenging, suggesting additional antioxidant activity relevant to the oxidative stress component of hyperuricemia.

How the Mouse Experiment Was Designed

To model hyperuricemia, the team gave mice oral doses of uric acid (5 mM) combined with oteracil potassium (0.4 mg/mL) for 21 days, an approach that chemically impairs uric acid excretion while flooding the system. Chemically induced hyperuricemia models using such agents are well-established tools for studying the condition's pathophysiology and screening potential therapies. The probiotic-treated group received 1 x 10^9 CFU/mL of the consortium daily alongside the hyperuricemia induction protocol.

The results across 21 days were measurable across multiple organ systems. Serum uric acid fell 32.57% in consortium-treated mice compared to the untreated hyperuricemic group. Creatinine and blood urea nitrogen, both markers of kidney stress, declined. Renal IL-1β (an inflammatory cytokine), xanthine oxidase activity, and malondialdehyde (an oxidative stress marker) all dropped. Histopathological staining confirmed reduced tubular dilatation and epithelial cell swelling in kidney tissue, and less hepatocyte ballooning in liver sections. The bacteria colonized successfully: qPCR of fecal samples confirmed the presence of both strains at day 14, with higher relative abundances in the consortium-treated and hyperuricemic-plus-consortium groups.

Gut microbiota composition shifted meaningfully. The consortium increased Firmicutes and Bacteroidota, and enriched beneficial genera including Lactobacillus, Akkermansia, and Bifidobacterium. Harmful taxa, including Desulfovibrio, Parasutterella, Helicobacter, and Bacteroides, declined. Short-chain fatty acid profiling by GC-MS found elevated fecal levels of acetic, propionic, butyric, and valeric acids in consortium-treated mice, pointing to improved fermentation and gut barrier support.

Unanswered Questions About Dosing, Duration, and Human Relevance

The most significant caveat here is the gap between a mouse model and a human patient. Every beneficial number above comes from an artificially induced hyperuricemia model in inbred mice, and translating microbiome-targeted interventions from animal studies to clinical trials is notoriously unreliable: human gut microbiota are far more variable, and endpoints that look clean in controlled animal experiments often fail to replicate. The authors themselves flag the absence of long-term outcome data and call for metabolomic profiling, transcriptomic analysis, and targeted knockout studies before any clinical claims can be made.

There is also the mechanistic question of how much of the effect comes from direct uric acid degradation by the bacteria versus secondary shifts in the gut microbiota versus reduced systemic inflammation. The study captures all three signals but does not isolate their contributions. Hepatic xanthine oxidase activity, for example, showed no significant change despite improvements in liver histology, which suggests the consortium's liver protection is not purely through enzyme inhibition.

What Comes Next for Kimchi-Derived Uric Acid Research

The authors recommend developing a probiotic product enriched with NEFU-3 and NEFU-4 and moving toward clinical validation. That road is long. Animal probiotic studies frequently demonstrate metabolic benefits that do not survive the translation to human trials due to species differences and the sheer complexity of human metabolic disease. Still, the mechanistic specificity here, named enzymes, confirmed colonization, quantified degradation products at days 7, 14, and 21 (17.21%, 29%, and 43.57% fecal UA reductions respectively), gives this work more traction than a simple "probiotics improve gut health" finding.

For the roughly one in five adults living with hyperuricemia and unsatisfied with current drug options, the idea that a traditional fermented food already consumed across Northeast China might harbor a targeted metabolic intervention is genuinely interesting. The strains are real, the pathway is mapped, and the mouse data are quantitatively solid. What they are not, yet, is proof that the same biology will play out in a human gut.

Evidence rating

INVESTIGATIONAL — 73/100

Caveats:

• All intervention data come from a mouse model of hyperuricemia; results have not been tested in humans.
• This is a single study with no independent replication.
• No funding source was disclosed, so potential conflicts of interest cannot be assessed.
• Long-term safety of these probiotic strains has not been evaluated.

This is a controlled animal study using a hyperuricemic mouse model; no human subjects were enrolled. The findings demonstrate a step-by-step mechanistic pathway and report specific effect sizes, but results are preliminary and have not been replicated in an independent cohort or translated to clinical populations. The absence of disclosed funding prevents full conflict-of-interest assessment.

References

1. Aman Khan, Xiaoyu Wang, Binyu Cui, et al. (2026). Northeast China Traditional Kimchi (Paocai) Probiotic Resources Metabolized Uric Acid and Relieved Hyperuricemia in Mice. eFood. https://doi.org/10.1002/efd2.70187
2. Hyperuricemia – StatPearls – NCBI Bookshelf. NIH. https://www.ncbi.nlm.nih.gov/books/NBK560767/
3. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364539/
4. Nurshad Ali (2026). Interactions between serum uric acid and gut microbiota: implications for metabolic health. Metabolism Open. https://doi.org/10.1016/j.metop.2025.100438
5. Senyue Zhang, Kaiqing Li, Hu Zhang, et al. (2025). Progress in animal models for studying hyperuricemia. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1636205
6. Raul de Jesus Cano, Gissel García Menéndez (2026). Why Clinical Trials of Microbiome-Targeted Interventions Often Fail to Support Health Claims: A Commentary on Probiotics and Translational Design. Microorganisms. https://doi.org/10.3390/microorganisms14020470
7. Penggang He, Qianyu Qu, Zhujun Zhong, Peibin Zeng (2023). Animal models for probiotics intervention on metabolic syndrome. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000002749